Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04747093

Induced-T Cell Like NK Cells for B Cell Malignancies

Induced-T Cell Like NK Cellular Immunotherapy for Refractory B Cell Malignancies

Sponsor: Nanfang Hospital, Southern Medical University

Conditions B Cell Leukemia B Cell Lymphoma B-cell Acute Lymphoblastic Leukemia B-cell Lymphoma Recurrent B-cell Lymphoma Refractory

Interventions CAR-ITNK cells

Updated 5 times since 2021 Last updated: Feb 6, 2021 Started: Jan 29, 2021 Primary completion: Dec 31, 2021 Completion: Mar 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on B Cell Leukemia and B Cell Lymphoma, this trial is ongoing. The trial is conducted by Nanfang Hospital, Southern Medical University and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Mar 2023 — Jul 2023 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Mar 2021 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanfang Hospital, Southern Medical University

Data source: Nanfang Hospital, Southern Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China